Added to YB: 2026-08-14
Pitch date: 2026-08-12
NRXS [neutral]
NeurAxis, Inc.
-0.63%
current return
Author Info
Care & Capital is a 23 year old value investor and Healthcare Equity Analyst in training. Sign up for the newsletter.
Company Info
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
Market Cap
$85.1M
Pitch Price
$6.32
Price Target
N/A
Dividend
N/A
EV/EBITDA
-11.20
P/E
-8.85
EV/Sales
14.49
Sector
Health Care Equipment and Supplies
Category
growth
NeurAxis ($NRXS) – Reports Q2 2026 results
NRXS (earnings): Q2'26 rev +116% YoY to $1.93M (below consensus, stock -8%), driven by new Category I CPT code effective Jan 2026. GM 85.9%, ASP up on mix shift to full-reimbursement. Net loss $0.19/sh. $8.3M cash, going-concern flag, dilution risk. VA contract + guideline inclusion strengthen access; large payer adoption is rate-limiter. Thesis intact. Long at $5.49.
Read full article (5 min)